Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2025-09-18 03:49Core Viewpoint - Heng Rui Medicine's stock surged over 7%, reaching a new high of 91 HKD, following the acceptance of its drug application for SHR-A1811 by the National Medical Products Administration [1] Group 1: Company Performance - Heng Rui Medicine's subsidiary received a "Notice of Acceptance" for the marketing license application of SHR-A1811, which is intended for treating HER2-positive breast cancer patients [1] - The company reported a net profit of 4.45 billion CNY for the first half of the year, marking a year-on-year increase of 29.67% [1] - In the second quarter of 2025, the net profit reached 2.58 billion CNY, reflecting a year-on-year growth of 24.88% [1] Group 2: Product Development and Market Position - The first half of 2025 saw a rapid increase in the release of innovative drugs, with international contributions to profits continuing to grow [1] - The company achieved 700 million USD in upfront licensing revenue so far in 2025, indicating strong overseas authorization growth [1] - A total of 15 self-developed innovative molecules entered clinical stages for the first time in the first half of 2025, showcasing the company's robust pipeline [1] Group 3: Future Outlook - The company is expected to maintain high-speed growth in innovative drugs over the next three years due to a continuously enriching pipeline [1] - The company is producing products with blockbuster potential, reinforcing its positive market outlook [1] - The recommendation to maintain a "buy" rating reflects confidence in the company's ongoing innovation and market performance [1]